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Abstract We examined the effect of l-palmitoyl-2-linoleoylgly-
cerol (PLG), PLG hydroxide (PLG-OH), and PLG hydroper-
oxide (PLG-OOH) on the release of superoxide anion from 
human PMNs monitored by the chemiluminescence generated by 
the superoxide anion-sensitive reagent, 2-methyl-6-(p-methoxy-
phenyl)-3,7-dihydroimidazo[l,2-«lpyrazin-3-one (MCLA). PLG-
OOH at low micromolar concentrations stimulated human 
PMNs whereas PLG and PLG-OH did not. 1,3-Dilinoleoylgly-
cerol hydroperoxide, l-palmitoyl-2-linoleoylphosphatidylcholine 
hydroperoxide, and linoleic acid hydroperoxide were much less 
efficient in stimulating human PMNs than PLG-OOH. The 
PKC inhibitors, chelerythrine chloride and staurosporine, 
inhibited the stimulation of PMNs. Possible pathophysiological 
role of 1,2-diacylglycerol hydroperoxides is discussed. 
© 1997 Federation of European Biochemical Societies. 
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O H can activate P K C even in the absence of calcium ion and 
phosphatidylserine [4]. It is therefore suggested that 1,2-di-
acylglycerol hydroperoxide (1 ,2-DAG-OOH) and hydroxide 
(1,2-DAG-OH) may activate the PKC-dependent signal trans-
duction system if these components are released from oxidized 
biomembranes by the action of phospholipase C [4]. 
To demonstrate that oxidized 1,2-diacylglycerol can act as a 
biochemical messenger in cellular systems, we have investi-
gated its activation of human polymorphonuclear leukocytes 
(PMN), since they are known to be activated by PMA [5] and 
since oxidized 1,2-diacylglycerol acts like P M A [4]. The acti-
vation of P M N s was assessed by measuring the superoxide 
anion released from P M N s . The production of superoxide 
anion was measured by a chemiluminescence method using 
a sea-firefly cypridina luciferin analogue, 2-methyl-6-(/?-meth-
oxyphenyl)-3,7-dihydroimidazo[l ,2-a]pyrazin-3-one (MCLA), 
as a luminescence reagent [6]. 
2. Materials and methods 
1. Introduction 
Protein kinase C (PKC) plays a crucial role in receptor-
mediated signal transduction affecting a diverse range of cel-
lular responses such as cell proliferation, differentiation, and 
tumor promotion [1,2]. PKC is known to be activated by 
calcium ion and lipids such as phosphatidylserine and 1,2-
diacylglycerol [1,2], and directly by phorbol 12-myristate 13-
acetate (PMA) [3]. We have recently reported that 1,2-dilino-
leoylglycerol hydroperoxide (1,2-LLG-OOH) and hydroxide 
(1,2-LLG-OH) activate P K C isolated from rat brain almost 
as efficiently as does P M A [4]. 1,2-LLG-OOH and 1,2-LLG-
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2.1. Materials 
1 -Palmitoyl-2-linoleoylphosphatidylcholine (PLPC), 1,3-dilinoleoyl-
glycerol (1,3-LLG), Bacillus cereus phospholipase C (type XI), soy-
bean lipoxidase (type IB), PMA, chelerythrine chloride, tert-buiy\ 
hydroperoxide, and superoxide dismutase (SOD) were purchased 
from Sigma Chemical Co. Staurosporine and 1 -(5-isoquinolinesulfo-
nyl)-2-methylpiperazine dihydrochloride (H-7) were purchased from 
Funakoshi (Tokyo). Linoleic acid hydroperoxide was prepared as pre-
viously described [7]. MCLA was purchased from Tokyo Kasei Ko-
gyo (Tokyo). Solvents and other reagents were of the highest analyt-
ical grade available. 
2.2. Preparation of diacylglycerol and its hydroperoxide and hydroxide 
PLPC hydroperoxide (PLPC-OOH) and its hydroxide (PLPC-OH) 
were prepared as described previously [8]. PLPC, PLPC-OOH, and 
PLPC-OH were individually hydrolyzed with Bacillus cereus phospho-
lipase C in 50 mM aqueous Tris-HCl (pH 7.4)/methanol (60:40, v/v) 
containing 5 mM calcium chloride at 37°C for 60 min. The resulting 
l-palmitoyl-2-linoleoylglycerol (PLG), PLG hydroperoxide (PLG-
OOH), and PLG hydroxide (PLG-OH) were extracted with chloro-
form/methanol (2:1, v/v) and the lower layer was concentrated using a 
rotary evaporator. PLG, PLG-OOH, and PLG-OH were purified by 
HPLC (Superiorex ODS column; 20X250 mm, 5 um, Shiseido, Ja-
pan) using methanol/2-propanol (85:15, v/v) as the mobile phase at a 
flow rate of 8 ml/min; their elution times were 33.7, 16.7, and 
16.7 min, respectively. 1,3-LLG hydroperoxide (1,3-LLG-OOH) was 
prepared by the aerobic autoxidation of 1,3-LLG for 3 days, and was 
purified from unreacted 1,3-LLG by HPLC as described above. 
The concentration of hydroperoxides was determined by using a 
hydroperoxide-specific, isoluminol chemiluminescence assay [7]. The 
absence of hydroperoxide in PLG-OH, PLG, and 1,3-LLG was also 
confirmed by this method. The concentration of PLG-OH was esti-
mated by its absorbance at 234 nm using an assumed molar extinction 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 ( 9 7 ) 0 0 8 2 3 - 5 
462 Y. Yamamoto et al.lFEBS Letters 412 (1997) 461^64 
coefficient, 28000 M _ 1 cm - 1 [9]. The concentration of PLG and 1,3-
LLG was calculated from their weights. 
2.3. Preparation of granulocytes 
Peripheral blood from a healthy human volunteer was drawn into a 
syringe containing heparin (20 U/ml). Leukocytes were isolated by 
sedimentation in the presence of 2.0% dextran followed by brief hy-
potonic lysis of residual erythrocytes [10]. The resultant leukocytes 
(1.0 X 107 cells/ml) containing > 90% PMN were suspended in Hanks' 
balanced salt solution (HBSS) containing 1.3 mM calcium ion and 
0.9 mM magnesium ion, and were kept at 0°C for no longer than 
3 h prior to use. Cell viability was determined by the trypan blue 
exclusion method [10]. 
2.4. Incubation system and the activation of PMNs 
A glass cuvette containing PMNs (1.5 or 2.5 X104 cells/ml) and 
MCLA (1 uM) in 2.0 ml of HBSS was placed in a luminescence reader 
(Type BLR-301, Aloka, Tokyo) and the emission of light was re-
corded [11]. After keeping the cuvette at 37°C under aerobic condi-
tions for 3 min, 10 ul of a 1.6 mM PLG-OOH in methanol (final 
concentration: 8 uM) was added to the cuvette by a microsyringe. 
PLG-OH, PLG, 1,3-LLG-OOH, and 1,3-LLG were added similarly 
instead of PLG-OOH. 20 ul of a 3.2 uM PMA in dimethyl sulfoxide/ 
HBSS (1:1, v/v) was also added in a control experiment. After the 
addition of stimulants, SOD (final concentration: 0.5 uM) was added 
to assess the role of superoxide anion in MCLA-dependent light emis-
sion from PMNs. PKC inhibitors were added 5 min before the addi-
tion of PLG-OOH or PMA. 
3. Results and discussion 
Fig. 1A shows that the addition of PLG-OOH (8 uM) im-
mediately induced a strong light emission from PMNs in the 
presence of MCLA at 37°C under aerobic conditions. This 
chemiluminescence is dependent on MCLA, since no detect-
able photon emission was observed in the absence of MCLA 
(data not shown). The chemiluminescence intensity sharply 
increases to reaching a maximum and then the signal decays 
with time. The stimulant-induced maximal luminescence in-
tensity (MLI) was calculated by subtracting the baseline lumi-
nescence intensity from the maximal intensity as shown in Fig. 
1A. The addition of a catalytic amount of SOD (0.5 u,M) 
suppressed the chemiluminescence intensity to a level which 
was smaller than the baseline luminescence intensity, indicat-
ing the involvement of superoxide anion in the MCLA-de-
pendent chemiluminescence from human PMNs. 
PMA also stimulated the MCLA-dependent light emission 
from PMNs and this was suppressed by the addition of SOD 
(Fig. IB), as observed previously [6]. Superoxide anion can 
reduce the oxidized form of cytochrome c [12] and the initial 
rate (maximal rate) of the reduction can be determined by 
measuring the increase in absorption of the reduced form of 
cytochrome c at 550 nm (emax = 2.11 X10
4 M" 1 cm"1) [12]. It 
was found that PMA-stimulated MLI at 10s counts/min (cpm) 
corresponded to the release of 0.095 nmol superoxide anion 
per minute. Thus, it was calculated that 8 uM PLG-OOH 
induced the release of superoxide anion from PMNs (3 X 104 
cells) at a maximal rate of 0.36 nmol/min. It is noteworthy 
that cytochrome c cannot be used for the measurement of 
superoxide anion production from PMNs stimulated by 
PLG-OOH since cytochrome c rapidly decomposes PLG-
OOH (unpublished data). 
Next, we examined the effect of PLG-OOH concentration 
on MCLA-dependent light emission from PMNs. As shown in 
Fig. 2, MLI from PMNs in the presence of MCLA increased 
with increasing PLG-OOH concentration to a maximum level 
at about 4 uM. Fig. 3 shows that 8 uM PLG-OOH induced 
the MCLA-dependent light emission from PMNs more 
strongly than the same concentration of 1,3-LLG-OOH. 
Moreover, PLPC-OOH, linoleic acid hydroperoxide, tert-bu-
tyl hydroperoxide, and hydrogen peroxide were much less 
efficient in stimulating human PMNs than PLG-OOH (data 
not shown), suggesting that the chemical structure of 1,2-di-
0.6 
CD 
O 
X 
E 
Q. 
O^ 
CD 
O 
CD 
o 
CO 
CD 
C 
£ 
CD 
o 
0.5 
0.4 
0.3 
"F 0.2 -
0.1 -
0.0 
A 
V 
\ 
\ SOD 
MLI \ , | X 
\ 
■I I I 1 L j i 
0 1 2 3 4 5 6 7 8 
Time (min) 
0.6 
CiP 
O 0.5 
X 
Q . 0 . 4 
CD 
O 
§ 0.3 
o 
CO 
CD 
~ 0.2 
_2 
0 0.1 
sz 
O 
n n 
-
- /x 
1 1 1 
B 
SOD 
1 
i i i i i i 
0 1 
Time (min) 
Fig. 1. Light emission from human PMNs (1.5 X 104 cells/ml) stimulated by (A) 8 uM PLG-OOH and (B) 32 nM PMA in the presence of 
1 uM MCLA in HBSS at 37°C under aerobic conditions. The stimulant was added at t = 0 and the addition of SOD (0.5 uM) is indicated by 
the arrows. 
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Fig. 2. The effect of PLG-OOH concentration on MLI from human 
PMNs (2.5 X 104 cells/ml) in the presence of 1 |xM MCLA in HBSS 
at 37°C under aerobic conditions. Vertical bars indicate standard 
deviation (n = 3). 
acylglycerol hydroperoxide is an essential feature for the stim-
ulation of PMNs. Fig. 3 also shows that 1,3-LLG, PLG, and 
PLG-OH did not stimulate the release of superoxide anion 
from PMNs as efficiently as PLG-OOH. There was a signifi-
cant difference between PLG-OOH and PLG-OH with respect 
to stimulation of PMNs. We also observed that PLG-OOH 
activated rat brain PKC more efficiently than PLG-OH did (S. 
Takekoshi et al., unpublished data) although 1,2-LLG-OOH 
and 1,2-LLG-OH activated the rat brain PKC with almost the 
same potency [4]. 
In order to verify the involvement of PKC in the stimula-
tion of PMNs by PLG-OOH, the effects of PKC inhibitors, 
chelerythrine chloride (20 uM) [13], staurosporine (0.5 uM) 
[14,15], and l-(5-isoquinolinylsulfonyl)-2-methylpiperazine di-
hydrochloride (H-7, 200 uM) [15], were examined. These in-
hibitors did not affect the viability of PMNs and were added 
to PMNs 5 min before the addition of stimulants, PLG-OOH 
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Fig. 3. MLI from human PMNs (2.5 X104 cells/ml) stimulated by 
8 uM lipid derivatives or 32 nM PMA in the presence of 1 |J,M 
MCLA in HBSS at 37°C under aerobic conditions. Horizontal bars 
indicate standard deviation (n = 3). 
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Fig. 4. Effects of PKC inhibitors (20 |i.M chelerythrine chloride, 
0.5 |xM staurosporine, and 200 |xM l-(5-isoquinolinylsulfonyl)-2-
methylpiperazine dihydrochloride (H-7) on 32 nM PMA or 8 |J,M 
PLG-OOH induced light emission from human PMNs (2.5 X104 
cells/ml) in the presence of 1 |xM MCLA in HBSS at 37°C under 
aerobic conditions. Horizontal bars indicate standard deviation 
(#1 = 3). 
and PMA. As shown in Fig. 4, chelerythrine chloride and 
staurosporine nearly suppressed all PMA-induced MLI from 
human PMNs while H-7 was effective by about 70%. These 
PKC inhibitors also suppressed PLG-OOH-stimulated MLI 
from human PMNs but to a lesser extent than stimulated 
by PMA (Fig. 4). These observation suggest that PLG-OOH 
stimulates PMNs primarily by activating PKC, but also that 
other activation system may be involved. It is also important 
to identify which PKC isozyme is responsible for PLG-OOH-
induced PMN activation; further investigation is being con-
sidered. 
Phosphatidylcholine-specific phospholipase C (PC-PLC), 
which catalyzes the hydrolysis of phosphatidylcholine to 1,2-
diacylglycerols, has been found in PMNs, lymphocytes, and 
hepatic cells [16]. Bacillus cereus PC-PLC can hydrolyze oxi-
dized and unoxidized phosphatidylcholine [17]. This was also 
confirmed in this study since PLG, PLG-OH, and PLG-OOH 
were prepared by the hydrolysis of PLPC, PLPC-OH, and 
PLPC-OOH, respectively, using Bacillus cereus PC-PLC. 
Although it is necessary to demonstrate that the mammalian 
PC-PLC hydrolyzes the oxidized phosphatidylcholine, 1,2-
DAG-OOH are expected to be formed as a result of oxidative 
stress. In fact, the oxidation of hepatocyte phospholipids and 
plasma lipoproteins gave PC-OOH as the major product 
[18,19]. 
This and data from previous studies [4] provide evidence 
that 1,2-DAG-OOH can act like PMA as a powerful tumor 
promoter. If the production of phospholipid hydroperoxides 
exceeds the capacity of hydroperoxide-reducing activity at or 
near an inflammation site, and phospholipase C is released 
from phagocytic cells or other sources, then 1,2-DAG-OOH 
may prevail and function as a physiological tumor promoter. 
It should be noted that chronic inflammation is attributed as 
one of the major cause of cancer [20]. 
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